Confident Outlook for BAT VUSE with Prediction of Balanced Profit by 2023

BAT by 2FIRSTS.ai
Dec.07.2023
Confident Outlook for BAT VUSE with Prediction of Balanced Profit by 2023
British American Tobacco (BAT) expresses confidence in its Vuse e-cigarette brand and predicts a balanced profit by 2023.

According to industry media outlet Journalnow's recent report, British American Tobacco expressed confidence once again on Wednesday in its product portfolio consisting of no-smoke nicotine and tobacco products led by the American e-cigarette brand Vuse.

 

According to the financial update for the tobacco company's 2023 fiscal year, it is expected that the new product category will achieve "rough breakeven" in 2023, two years ahead of the initial projections.

 

The confidence of British American Tobacco in e-cigarettes, glo heated tobacco, and oral products is increasing, and it is expected that the sales of these products will account for 50% of its revenue by 2035. Currently, Vuse products are already available in 50 global markets.

 

British American Tobacco has also confirmed that it expects to achieve its projected earnings growth guidance of 3% to 5% in the fiscal year 2023. The company intends to release its financial report for the 2023 fiscal year in February 2024.

 

Tadeu Marroco, who was promoted to President and CEO of British American Tobacco in May, expressed his encouragement at the strong performance and significant revenue and profit growth driven by sales of Vuse and Velo. Additionally, the company is continuing to drive the recovery of its traditional cigarette sales in the United States.

 

He stated, "We have clearly stated that the recovery of the incendiary products in the United States will take time." However, he is confident in the actions to be taken, believing that this will strengthen the company's product portfolio in the long term.

 

Marlboro stated that British American Tobacco has completed a thorough and comprehensive review of its business in the United States.

 

He stated, "As a result, we have already started and will continue to invest in improving our investment portfolio management, strengthening our market channels, and further expanding our extensive, digitally-driven revenue growth management capabilities. We believe this will bring greater resilience during economic cycles."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA announced it will convene a Feb. 10, 2026 roundtable with small tobacco product manufacturers to gather feedback on PMTA submissions for ENDS products. The discussion will be viewable online, and a public docket is open for comments through March 12, 2026.
Feb.10 by 2FIRSTS.ai
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea to regulate synthetic-nicotine e-liquids as tobacco from April 24
South Korea’s Health Ministry says amendments to the Tobacco Business Act will take effect on April 24, bringing synthetic-nicotine e-liquid vapes under the legal definition of tobacco. The shift extends cigarette-style rules to these products, including mandatory graphic warnings, sharply limited advertising channels, stricter vending-machine placement requirements, and a ban on use in smoke-free areas, with enforcement checks slated from late April.
Feb.03 by 2FIRSTS.ai
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
The U.S. International Trade Commission (ITC) has terminated Investigation 337-TA-1410 after invalidating key vape patent claims asserted by R.J. Reynolds Vapor Company, removing the immediate risk of import bans for dozens of companies. However, a new case—337-TA-1486—has already opened a more consequential legal front, shifting the focus from patent disputes to regulatory compliance across the vape supply chain, including PACT Act reporting, tax compliance, and FDA marketing authorization.
BAT
Mar.11
China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Company Limited announced its audited results for the year ended December 31, 2025. Revenue was HK$14.58 billion, profit before taxation was HK$1.28 billion, and profit attributable to owners of the Company was HK$0.98 billion, with basic and diluted EPS of HK$1.42. The Board proposed a final dividend of HK$0.33 per share; together with an interim dividend of HK$0.19 per share, the full-year dividend totaled HK$0.52 per share.
Mar.06 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11